Outgoing Promoter Reclassified to Public Category for Vilin Bio Med Limited After Open Offer Conclusion
Following the successful conclusion of its Open Offer, Vilin Bio Med Limited confirmed the reclassification of its outgoing promoters to the public category. The development confirms the transfer of management and control of the company to the Acquirer(s), who have been established as the new promoters.The Open Offer involved the acquisition of 36,27,000 Equity Shares, representing 26% of the Voting Share Capital of Vilin Bio Med Limited, and successfully concluded on September 15, 2025. With the execution of the Share Purchase Agreement dated March 27, 2025, the management and control of the company shifted to the Acquirer(s).
According to the company, the outgoing promoter group is classified as 'Public' upon the completion of the Open Offer. The following outgoing promoter satisfied the necessary criteria for this reclassification:
| Name of the Outgoing Promoter(s) / Promoter Group | Number of Equity Shares Held | % of Total Voting Capital |
|---|---|---|
| Mr. Devireddy Srinivas Reddy | 4,45,425 | 3.19 |
The company confirmed that the outgoing promoter met all required conditions for this re-classification status. Key confirmations included:
- The promoter does not hold more than Ten Percent (10%) of the Total Voting Rights in the company.
- The promoter does not exercise control over the affairs of the company directly or indirectly.
- The promoter does not have any Special Rights with respect to the company through formal or informal arrangements, including any Shareholder Agreements.
- The promoter is not represented on the Board of Directors, including as a Nominee Director, of the company.
- The promoter shall not act as a Key Managerial Person (KMP) in the company for a period of three (3) years from the date of re-classification.
- The promoter is not categorized as 'Wilful Defaulters' or 'Fugitive Economic Offenders.'
VILINBIO Stock Price Movement
On Monday, Vilin Bio Med Limited shares tumbled by 21.36% after settling at ₹38.85. The stock saw a sharp decline from its previous close of ₹49.4, indicating a significant loss of value for investors in the pharmaceutical sector.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.